Zoledronic acid enhances tumor growth and metastatic spread in a mouse model of jaw osteosarcoma
ORAL DISEASES(2024)
Abstract
ObjectivesInvestigation of the therapeutic effect of zoledronic acid (ZA) in a preclinical model of jaw osteosarcoma (JO).Materials and MethodsThe effect of 100 mu g/kg ZA administered twice a week was assessed in a xenogenic mouse model of JO. The clinical (tumor growth, development of lung metastasis), radiological (bone microarchitecture by micro-CT analysis), and molecular and immunohistochemical (TRAP, RANK/RANKL, VEGF, and CD146) parameters were investigated.ResultsAnimals receiving ZA exhibited an increased tumor volume compared with nontreated animals (71.3 +/- 14.3 mm3 vs. 51.9 +/- 19.9 mm3 at D14, respectively; p = 0.06) as well as increased numbers of lung metastases (mean 4.88 +/- 4.45 vs. 0.50 +/- 1.07 metastases, respectively; p = 0.02). ZA protected mandibular bone against tumor osteolysis (mean bone volume of 12.81 +/- 0.53 mm3 in the ZA group vs. 11.55 +/- 1.18 mm3 in the control group; p = 0.01). ZA induced a nonsignificant decrease in mRNA expression of the osteoclastic marker TRAP and an increase in RANK/RANKL bone remodeling markers.ConclusionThe use of bisphosphonates in the therapeutic strategy for JO should be further explored, as should the role of bone resorption in the pathophysiology of the disease.
MoreTranslated text
Key words
bisphosphonates,bone resorption,mandible,osteosarcoma,tumor microenvironment
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined